OncoMatch/Clinical Trials/NCT07181720
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Is NCT07181720 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CD70-targeted CAR-T cells and CD70-targeted CAR-T cells for renal cell carcinoma (rcc).
Treatment: CD70-targeted CAR-T cells · CD70-targeted CAR-T cells · CD70-targeted CAR-T cells — This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Thyroid Cancer
Ovarian Cancer
Cervical Cancer
Biomarker criteria
Required: CD70 overexpression (IHC 3+ score) (IHC 3+)
tumors with positive CD70 expression, confirmed histopathologically with IHC 3+ score
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tyrosine kinase inhibitor
Failed or intolerant to standard second-line treatments (at least one of the following: tyrosine kinase inhibitors (TKIs), poly(ADP-ribose) polymerase inhibitors (PARPi), anti-angiogenic therapy; disease progression or inability to tolerate surgery, chemotherapy, radiotherapy, or targeted therapy)
Must have received: PARP inhibitor
Failed or intolerant to standard second-line treatments (at least one of the following: tyrosine kinase inhibitors (TKIs), poly(ADP-ribose) polymerase inhibitors (PARPi), anti-angiogenic therapy; disease progression or inability to tolerate surgery, chemotherapy, radiotherapy, or targeted therapy)
Must have received: anti-angiogenic therapy
Failed or intolerant to standard second-line treatments (at least one of the following: tyrosine kinase inhibitors (TKIs), poly(ADP-ribose) polymerase inhibitors (PARPi), anti-angiogenic therapy; disease progression or inability to tolerate surgery, chemotherapy, radiotherapy, or targeted therapy)
Cannot have received: anti-CD70 therapy
Prior treatment with anti-CD70 therapies
Lab requirements
Blood counts
white blood cell count >2.0×10⁹/l, neutrophils >0.8×10⁹/l, lymphocytes >0.5×10⁹/l, platelets >50×10⁹/l, hemoglobin >90g/l
Kidney function
serum creatinine ≤2.0×uln
Liver function
alt and ast ≤3.0×uln (may be relaxed to ≤5.0×uln in cases with liver tumor infiltration); total bilirubin ≤2.0×uln (may be relaxed to ≤3.0×uln in cases with gilbert's syndrome or liver tumor infiltration)
Cardiac function
echocardiogram showing left ventricular ejection fraction (lvef) ≥50%, and ecg with no significant abnormalities
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify